Skip to main
IDXX

IDEXX Laboratories (IDXX) Stock Forecast & Price Target

IDEXX Laboratories (IDXX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 44%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

IDEXX Laboratories demonstrates strong customer retention rates of approximately 97%, enhancing the predictability of its revenue and earnings streams. The company has achieved a notable compound annual growth rate (CAGR) of around 16% in organic consumables revenue from 2016 to 2022, reflecting durable growth in its recurring revenue segment. Moreover, IDXX's total suite of offerings has resulted in customers exhibiting 3.5 times higher growth across all testing categories, positioning the company favorably for continued expansion in the pet care market.

Bears say

IDEXX Laboratories has experienced a decline in clinical vet visits, with a year-over-year decrease of -1.7% in Q4 2025, signaling a concerning trend compared to previous quarters. This downturn is further compounded by a projected decline of 200 basis points in end market pet visits for 2026, predominantly attributed to constraints faced by lower income pet owners. Additionally, economic challenges could impact both customers and suppliers, potentially leading to reduced demand for IDEXX's products and hampered financial performance.

IDEXX Laboratories (IDXX) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 44% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IDEXX Laboratories and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IDEXX Laboratories (IDXX) Forecast

Analysts have given IDEXX Laboratories (IDXX) a Buy based on their latest research and market trends.

According to 9 analysts, IDEXX Laboratories (IDXX) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $709.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $709.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IDEXX Laboratories (IDXX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.